COCHLEAR LIMITED (COH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

COH - COCHLEAR LIMITED
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.41
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS
Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$272.29
01 Dec |
OPEN $273.81 |
HIGH $274.70 |
179,545 LOW $270.39 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 70% |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 457.1 | 553.5 | xxx |
DPS (cps) | xxx | 330.0 | 388.4 | xxx |
EPS Growth | xxx | 4.0% | 21.1% | xxx |
DPS Growth | xxx | 10.0% | 17.7% | xxx |
PE Ratio | xxx | N/A | 49.2 | xxx |
Dividend Yield | xxx | N/A | 1.4% | xxx |
Div Pay Ratio(%) | xxx | 72.2% | 70.2% | xxx |
Last ex-div: 18/09 - ex-div 175c (franking 70%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 457.1 |
DPS All | xxx | xxx | xxx | xxx | xxx | 330.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 1,955.7 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 2,662.9 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 362.4 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 15.37 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 17.50 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 15.94 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 11.94 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 17.50 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 21.20 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 115.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 39 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 163 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 202 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 256 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 556 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 8.60 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 95.9 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 4.90 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 488 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 1,055 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 245 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 99 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
COH STOCK CHART

FNArena News on COH
1 |
Rudi’s View: Quality In Stocks; What Is It Good For?Nov 22 2023 - Rudi's View |
2 |
ESG Focus: Rounding Up A Psychosocial FY23 SeasonNov 20 2023 - ESG Focus |
3 |
ESG Focus: Day Of The TRIFRSNov 09 2023 - ESG Focus |
4 |
Australian Broker Call *Extra* Edition – Nov 08, 2023Nov 08 2023 - Daily Market Reports |
5 |
Rudi’s View: Outlook 2024, Is History Our Guide?Nov 08 2023 - Rudi's View |
Latest Medical Equipment & Devices News
1 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
2 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
3 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |
4 |
Margins Signal Integral Diagnostics RecoverySep 07 2023 - Australia |
5 |
ResMed: Finding A Base?Aug 15 2023 - Technicals |
6 |
August Turns ResMed Into Nigel NoMatesAug 09 2023 - Australia |
7 |
Dr Boreham’s Crucible: Lumos DiagnosticsJun 19 2023 - Small Caps |
8 |
Fisher & Paykel Healthcare: Lower Margin, Higher SpendingMay 30 2023 - Australia |
9 |
Dr Boreham’s Crucible: ImpedimedMay 08 2023 - Small Caps |
10 |
Treasure Chest: ResMed’s Benevolent MonopolyMay 01 2023 - Treasure Chest |